The company is developing novel, easy-to-use and affordable ophthalmic instruments utilising polarised light technology. The first focus is on screening people for low macular pigment density, which is an early predictor of age-related macular degeneration (AMD). AMD is a serious problem for upwards of 150m people worldwide and it cannot be cured. There are simple preventative measures available so early detection could be a major breakthrough.